Option Care Health’s (OPCH) “Outperform” Rating Reaffirmed at Barrington Research

Barrington Research restated their outperform rating on shares of Option Care Health (NASDAQ:OPCH) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $38.00 price target on the stock. Barrington Research also issued estimates for Option Care Health’s FY2024 earnings at $1.15 EPS, Q1 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.37 EPS, FY2025 earnings at $1.35 EPS and FY2026 earnings at $1.55 EPS.

Separately, Jefferies Financial Group boosted their price target on shares of Option Care Health from $36.00 to $38.00 and gave the company a buy rating in a research report on Monday, March 4th.

Option Care Health Trading Up 1.1 %

Shares of OPCH opened at $29.61 on Wednesday. The firm’s fifty day moving average is $31.96 and its two-hundred day moving average is $31.48. The company has a quick ratio of 1.33, a current ratio of 1.77 and a debt-to-equity ratio of 0.74. The stock has a market cap of $5.15 billion, a PE ratio of 19.48, a price-to-earnings-growth ratio of 1.43 and a beta of 1.22. Option Care Health has a 52-week low of $24.23 and a 52-week high of $35.74.

Option Care Health (NASDAQ:OPCH) last announced its quarterly earnings results on Tuesday, April 23rd. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.04. The firm had revenue of $1.15 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. The company’s revenue was up 12.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS. Research analysts forecast that Option Care Health will post 1.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. purchased 35,000 shares of the business’s stock in a transaction on Monday, February 26th. The shares were bought at an average cost of $31.55 per share, for a total transaction of $1,104,250.00. Following the completion of the purchase, the director now directly owns 269,528 shares of the company’s stock, valued at $8,503,608.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.64% of the company’s stock.

Institutional Trading of Option Care Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Vontobel Holding Ltd. increased its stake in shares of Option Care Health by 2.9% during the third quarter. Vontobel Holding Ltd. now owns 13,168 shares of the company’s stock worth $426,000 after buying an additional 374 shares during the period. IFP Advisors Inc increased its stake in shares of Option Care Health by 20,350.0% during the third quarter. IFP Advisors Inc now owns 2,454 shares of the company’s stock worth $79,000 after buying an additional 2,442 shares during the period. SG Americas Securities LLC increased its stake in shares of Option Care Health by 1,638.4% during the third quarter. SG Americas Securities LLC now owns 84,729 shares of the company’s stock worth $2,741,000 after buying an additional 79,855 shares during the period. State of Alaska Department of Revenue increased its stake in shares of Option Care Health by 4.3% during the third quarter. State of Alaska Department of Revenue now owns 21,376 shares of the company’s stock worth $691,000 after buying an additional 880 shares during the period. Finally, Avior Wealth Management LLC increased its stake in shares of Option Care Health by 30.5% during the third quarter. Avior Wealth Management LLC now owns 15,706 shares of the company’s stock worth $508,000 after buying an additional 3,670 shares during the period. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.